• Newton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases

    Thursday September 9th 2021

  • Novalis Biotech Acceleration invests in San Francisco-based Modality.AI - technology that ‘self-drives’ neurological and psychiatric assessments

    Friday September 3rd 2021

  • Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands

    Thursday July 15th 2021

  • Biotalys completes its €47.5m initial public offering on Euronext Brussel

    Wednesday July 7th 2021

  • EIB boosts innovative biotech company Univercells with €30 million of European financing to support COVID-19-related projects

    Friday July 2nd 2021

  • Bone Therapeutics secures up to €16 million loan financing from the European Investment Bank to accelerate ongoing clinical and commercial development of innovative orthopedic treatments

    Thursday July 1st 2021

  • Newton Biocapital invests in EditForce to support development of a unique DNA/RNA editing platform based on PPR protein technology

    Wednesday June 30th 2021

  • Novalis Biotech closes €25 million Biotech Acceleration Fund

    Wednesday June 30th 2021

  • Your news here?

  • Biotalys launches its Initial Public Offering on Euronext Brussels

    Wednesday June 23rd 2021

  • Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy

    Tuesday June 22nd 2021

  • Biotalys announces intention to launch an Initial Public Offering on Euronext Brussels

    Tuesday June 15th 2021


Strategic Partners